BioStock: Elicera continues to deliver proof-of-concept data

Swedish cell and gene therapy company Elicera Therapeutics has achieved preclinical proof-of-concept in two of its immuno-oncology projects. iTANK, a universal CAR T-cell enhancement technology platform, reached proo-of-concept late last year, and the data was published in a high impact journal earlier this month.  Most recently, Elicera announced concluding proof-of-concept studies with ELC-201, a next-generation oncolytic virus aimed at treating a wide range of tumour indications.

Read the article at biostock.se:

https://www.biostock.se/en/2022/04/elicera-continues-to-deliver-proof-of-concept-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/